Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo takes on recurrent brain tumors

NCT ID NCT05484622

Ongoing Disease control Sponsor: Institut de Recherches Internationales Servier Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether combining two drugs—vorasidenib and pembrolizumab—can help people with a specific type of brain tumor (IDH-1 mutant glioma) that has come back or is growing. About 60 participants will receive the drugs before and after surgery to remove their tumor. The main goals are to check safety and see how the drugs affect immune cells in the tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
vorasidenib and pembrolizumab
What this could lead to
If it works, this could point toward a new combination treatment for a type of brain tumor that has come back.
What could go wrong
This is a very early phase 1 trial with only 60 people, so it is mainly checking safety and dosing. It may not lead to a proven treatment, and side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) oligodendroglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTROCYTOMA OLIGODENDROGLIOMA

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Dana-Farber Cancer Institute (Site: 840139)

    Boston, Massachusetts, 02215, United States

  • Duke University (Site: 840110)

    Durham, North Carolina, 27705, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21287, United States

  • MD Anderson Cancer Center (Site: 840102)

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital (Site: 840104)

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic Florida

    Cleveland, Ohio, 44195, United States

  • Memorial Sloan Kettering Cancer Center (Site: 840117)

    New York, New York, 10017, United States

  • Northwestern University (Site: 840123)

    Chicago, Illinois, 60045, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35249, United States

  • University of California, Los Angeles (Site: 840113)

    Los Angeles, California, 90095, United States

  • University of California, San Francisco (Site: 840149)

    San Francisco, California, 94013, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Miami (Site: 840129)

    Miami, Florida, 33136, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Pennsylvania Health System

    Philadelphia, Pennsylvania, 19104, United States

  • University of Utah, Huntsman Cancer Center

    Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.